TABLE 1.
Characteristics of 190 KTRs, stratified by antibody response >4160 AU/ml.
| Variable | All (N = 190) | Response (N = 52, 27%) a | No Response (N = 138, 72%) a | p-value |
|---|---|---|---|---|
| Age (years) (mean, SD) | 59.03 (12.35%) | 54.58 (11.86) | 60.71 (12.16) | 0.002 |
| Female gender (No., percentage) | 61 (32.11%) | 21 (40.38%) | 40 (28.99%) | 0.133 |
| Time from transplantation (years) (mean, SD) | 7.48 (7.98) | 6.62 (6.41) | 7.80 (8.49) | 0.363 |
| Living donor (No., percentage) | 147 (77.37%) | 47 (90.38%) | 100 (72.46%) | 0.008 |
| eGFR (per ml/min/1.73m2) (mean, SD) | 61.13 (21.48) | 70.01 (20.93) | 57.78 (20.78) | 0.001 |
| Diabetes mellitus (No., percentage) | 37 (19.47%) | 5 (9.62%) | 32 (23.19%) | 0.035 |
| Baseline log antibody level (mean, SD) | 1.31326 (0.905) | 2.34099 (0.515) | 0.925999 (0.692) | <0.001 |
| Time from second vaccine dose (days) (mean, SD) | 163.38 (1841.01%) | 160.96 (2,354.15%) | 164.3178 (1,600.00%) | 0.275 |
| Immunosuppression reduction (yes) (No., percentage) | 27 (14.21%) | 9 (17.31%) | 18 (13.04%) | 0.425 |
| BMI (per kg/m2) (mean, SD) | 27.22 (4.43) | 27.30 (4.12) | 27.19 (4.56) | 0.877 |
| High antimetabolite dose b (No., percentage) | 120 (63.16%) | 32 (61.54%) | 88 (63.77%) | 0.776 |
| High tacrolimus level c (No., percentage) | 110 (57.89%) | 25 (48.08%) | 85 (61.59%) | 0.092 |
| mTOR inhibitor (No., percentage) | 17 (8.95%) | 5 (9.62%) | 12 (8.70%) | 0.843 |
| Treatment with ATG (No., percentage) | 8 (4.21%) | 1 (1.92%) | 7 (5.07%) | 0.335 |
| Cyclosporine use (No., percentage) | 30 (15.79%) | 10 (19.23%) | 20 (14.49%) | 0.425 |
eGFR, estimated glomerular filtration; mTOR, mammalian target of rapamycin; ATG, anti thymocyte globulin.
a
Response for this analysis was considered if antibody level increased beyond 4160 AU/ml.
b
High antimetabolite dose ≥720 mg per day.
c
High tacrolimus level >7 mg/ml.